Advertisement
Advertisement

Gaucher's Disease Treatment

By Dr Ananya Mandal, MD

Gaucher's disease is a genetic disorder that leads to a lack of the enzyme glucocerebrosidase. This deficiency leads to the fatty substance glucocerebroside accumulating in important tissues and organs.

Gaucher’s disease is divided into three main forms which are grouped as follows:

  • Type 1 - This is the most common form of Gaucher’s disease. The brain is not affected and the condition is also referred to as the non-neuropathic form.
  • Type 2 - This form of Gaucher’s disease severely affects the brain and is common among infants and babies. Most children with this form of Gaucher’s disease do not live past the age of three years.
  • Type 3 - Here, the liver and spleen are enlarged and the brain is also slowly involved. This form of the condition often affects people in their childhood or adolescence.

Enzyme replacement therapy

Although there is no cure for Gaucher’s disease, it can be treated with enzyme replacement therapy, which can help improve symptoms and prevent irreversible damage. The deficient enzyme is replaced with an artificial enzyme which is administered intravenously every two weeks.

One example is Cerezyme. At first, patients need to be given the treatment in hospital, but the therapy can eventually be managed at home. Some of the adverse effects of this drug include itching, burning, rashes and swelling at the site of injection, allergic reactions after injection, nausea, diarrhea, abdominal pain, fever, chills, dizziness, headache, backache and palpitations.

Substrate reduction therapy

Another therapy that is available is substrate reduction therapy, which interrupts the production of glucocerebroside precursors, therefore preventing the build-up of this fatty substance in cells. An example of this form of therapy is Zavesca (miglustat), which may be used to treat mild to moderate Gaucher’s disease in cases that are not responsive to enzyme replacement therapy. Some of the common side effects associated with miglustat include abdominal upset, nausea, vomiting, diarrhea, flatulence, weight loss, headache and dizziness.

Reviewed by , BSc

Further Reading

Last Updated: Jun 24, 2014

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post